Cargando…

Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized controlled clinical trial

AIMS: To evaluate the effects of separate and combined use of the sodium‐glucose cotransporter‐2 (SGLT2) inhibitor dapagliflozin and the glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) exenatide on measures of kidney function. METHODS: In this prespecified secondary analysis of the DECREASE trial...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Ruiten, Charlotte C., van der Aart‐van der Beek, Annemarie B, IJzerman, Richard G., Nieuwdorp, Max, Hoogenberg, Klaas, van Raalte, Daniël H, Heerspink, Hiddo J. L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360098/ https://www.ncbi.nlm.nih.gov/pubmed/33908691 http://dx.doi.org/10.1111/dom.14410

Ejemplares similares

Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: Pooled analysis of randomized active controlled clinical trials
por: van der Aart ‐ van der Beek, Annemarie B., et al.
Publicado: (2020)

Brain Activation in Response to Low-Calorie Food Pictures: An Explorative Analysis of a Randomized Trial With Dapagliflozin and Exenatide
por: van Ruiten, Charlotte C., et al.
Publicado: (2022)

Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial
por: van Ruiten, Charlotte C., et al.
Publicado: (2022)

Effects of Dapagliflozin and Combination Therapy With Exenatide on Food-Cue Induced Brain Activation in Patients With Type 2 Diabetes
por: van Ruiten, Charlotte C, et al.
Publicado: (2022)

The incretin pathway as a therapeutic target in diabetic kidney disease: a clinical focus on GLP-1 receptor agonists
por: van Baar, Michaël J. B., et al.
Publicado: (2019)

Combination therapy with exenatide decreases the dapagliflozin‐induced changes in brain responses to anticipation and consumption of palatable food in patients with type 2 diabetes: A randomized controlled trial
por: van Ruiten, Charlotte C., et al.
Publicado: (2022)

Renal haemodynamic response to sodium‐glucose cotransporter‐2 inhibition does not depend on protein intake: An analysis of three randomized controlled trials
por: van der Aart‐van der Beek, Annemarie B., et al.
Publicado: (2021)

Effect of once‐weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the EXSCEL trial
por: van der Aart‐van der Beek, Annemarie B., et al.
Publicado: (2020)

Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study
por: Beernink, Jelle M., et al.
Publicado: (2023)

Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial
por: Persson, Frederik, et al.
Publicado: (2021)

Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial
por: Wheeler, David C, et al.
Publicado: (2021)

Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly
por: Shaw, Jonathan E., et al.
Publicado: (2017)

Using Exenatide Twice Daily or Insulin in Clinical Practice: Results from CHOICE
por: Mathieu, Chantal, et al.
Publicado: (2013)

Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION‐8 randomized controlled trial
por: Frías, Juan P., et al.
Publicado: (2018)

Efficacy and safety of exenatide once‐weekly vs exenatide twice‐daily in Asian patients with type 2 diabetes mellitus
por: Ji, Linong, et al.
Publicado: (2013)

Efficacy and safety of once‐weekly exenatide after switching from twice‐daily exenatide in patients with type 2 diabetes
por: Watanabe, Yuusuke, et al.
Publicado: (2019)

Exposure–Response Analysis of the Sodium–Glucose Cotransporter-2 Inhibitors Dapagliflozin and Empagliflozin on Kidney Hemodynamics in Patients with Type 2 Diabetes
por: van der Hoek, Sjoukje, et al.
Publicado: (2023)

Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes
por: Wolffenbuttel, B. H. R., et al.
Publicado: (2016)

Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes
por: Wysham, Carol H., et al.
Publicado: (2017)

Estimating the real world daily usage and cost for exenatide twice daily and liraglutide in Germany, the Netherlands, and the UK based on volumes dispensed by pharmacies
por: McDonell, Amanda L, et al.
Publicado: (2015)

Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study
por: Simó, Rafael, et al.
Publicado: (2015)

Editorial: Sodium Glucose Co-Transporter 2 Inhibitors and Kidney Function
por: Van Raalte, Daniel H., et al.
Publicado: (2022)

Evaluation of the Pharmacokinetics and Exposure–Response Relationship of Dapagliflozin in Patients without Diabetes and with Chronic Kidney Disease
por: van der Aart-van der Beek, Annemarie B., et al.
Publicado: (2021)

Randomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650 Versus Twice-Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes
por: Henry, Robert R., et al.
Publicado: (2013)

Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily1
por: Best, J H, et al.
Publicado: (2009)

Patients with Type 2 Diabetes Initiating Exenatide Twice Daily or Insulin in Clinical Practice: CHOICE Study
por: Matthaei, Stephan, et al.
Publicado: (2012)

Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes
por: Ridge, T, et al.
Publicado: (2012)

Combined antidiabetic benefits of exenatide and dapagliflozin in diabetic mice
por: Tatarkiewicz, K, et al.
Publicado: (2014)

Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial
por: Vardeny, Orly, et al.
Publicado: (2022)

Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers
por: Chiquette, Elaine, et al.
Publicado: (2012)

Long‐term safety and efficacy of exenatide twice daily in Japanese patients with suboptimally controlled type 2 diabetes
por: Inagaki, Nobuya, et al.
Publicado: (2011)

Efficacy of Exenatide Administered Twice Daily in Body Mass Index Reduction in Patients with Type 2 Diabetes Mellitus
por: Zhang, Jie, et al.
Publicado: (2022)

The effects of dapagliflozin on cardio‐renal risk factors in patients with type 2 diabetes with or without renin‐angiotensin system inhibitor treatment: a post hoc analysis
por: Scholtes, Rosalie A., et al.
Publicado: (2019)

Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapy
por: Tobin, G S, et al.
Publicado: (2012)

Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial
por: Scholtes, Rosalie A., et al.
Publicado: (2021)

Switching to Once-Daily Liraglutide From Twice-Daily Exenatide Further Improves Glycemic Control in Patients With Type 2 Diabetes Using Oral Agents
por: Buse, John B., et al.
Publicado: (2010)

Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial
por: Butt, Jawad H., et al.
Publicado: (2022)

A review of glycemic efficacy of liraglutide once daily in achieving glycated hemoglobin targets compared with exenatide twice daily, or sitagliptin once daily in the treatment of type 2 diabetes
por: Alshali, Khalid Z., et al.
Publicado: (2016)

Exenatide and Dapagliflozin Combination Enhances Sertoli Cell Secretion of Key Metabolites for Spermatogenesis
por: Ribeiro, João C., et al.
Publicado: (2022)

The Adaptive Renal Response for Volume Homeostasis During 2 Weeks of Dapagliflozin Treatment in People With Type 2 Diabetes and Preserved Renal Function on a Sodium-Controlled Diet
por: Scholtes, Rosalie A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vh63t2npb7jg2hllofg98ueksk